...
首页> 外文期刊>International Journal of Neuroscience >Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon-1a in Iran
【24h】

Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon-1a in Iran

机译:在伊朗皮下干扰素-1a治疗的患者患者的健康相关生活质量

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Multiple sclerosis (MS) requires long-term therapy and can affect many aspects of a patient's life, including quality of life. MS patients score lower on health-related quality of life (HRQoL) measures. The efficacy of subcutaneous interferon (IFN) -1a has been extensively evaluated by using objective measures but its impact on HRQoL is currently unclear. In this observational study, we evaluated HRQoL of Iranian patients with relapsing-remitting MS (RRMS) treated with IFN -1a by using short-form 36 (SF-36) and multiple sclerosis international quality of life (MusiQoL) questionnaires. Methods: Four hundred recruited RRMS patients were treated with human serum album free IFN -1a for 1 year. Patients were required to fill in SF-36 and MusiQoL questionnaires at the first visit and at each follow-up visit. Expanded disability status scale (EDSS) evaluation was performed at baseline and at each visit. Comparisons in HRQoL between visits were calculated using Cohen's d effect size. The relationship between change in EDSS score and the score of each questionnaire was calculated using Pearson correlation coefficients. Results: Three-hundred and eighty three completed the study. Two-hundred and thirty nine were female. Mean (SD) age was 28.75 (+/- 5.49). After 1 year, overall MusiQoL Index score effect size was -0.16 and SF-36 physical component and mental component showed overall effect sizes of -0.28 and -0.53, respectively. Mean (range) EDSS change was 1 (1-4). Three-hundred and seventy four were clinically stable with mean (range) EDSS change of 0.1 (-2-0.5). Increase in EDSS was linked to a decrease in both MusiQoL and SF-36. Conclusion: We found that, HRQoL did not change significantly over the first year of therapy. Furthermore, decreases in HRQoL were inversely correlated with increases in EDSS score.
机译:目的:多发性硬化症(MS)需要长期治疗,并可能影响患者生命的许多方面,包括生活质量。女士患者对健康相关的生活质量(HRQOL)措施得分降低。通过使用客观测量,皮下干扰素(IFN)-1a的功效已广泛评估,但其对HRQOL的影响目前不清楚。在这种观察性研究中,我们通过使用短型36(SF-36)和多发性硬化国际生活质量(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷(Musiqol)问卷质量(Musiqol)调查问卷进行评估伊朗患者的HRQOL。方法:四百名募集的RRMS患者用人血清专辑免费IFN -1a治疗1年。在第一次访问和每次随访访问时,患者需要填写SF-36和Musiqol问卷。扩展的残疾状态规模(EDS)评估在基线和每次访问时进行。使用Cohen的D效应大小计算访问之间的HRQOL比较。使用Pearson相关系数计算EDSS分数与每个问卷的分数之间的关系。结果:三百八十三名完成研究。女性两百三十九是女性。平均值(SD)年龄为28.75(+/- 5.49)。 1年后,总体QOL指数分数效应尺寸为-0.16,SF-36物理成分和精神组分分别显示出-0.28和-0.53的整体效果大小。平均值(范围)EDSS改变为1(1-4)。三百七十四个临床上稳定,平均值(范围)EDSSSsssssssssssssssssssssssssssss0.1(-2-0.5)。 EDS的增加与Musiqol和SF-36的减少相关联。结论:我们发现,HRQOL在治疗的第一年没有显着变化。此外,HRQOL的降低与EDSS分数的增加相反。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号